5-异丙基尿嘧啶 | 17432-95-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-异丙基尿嘧啶
• 英文名称: 5-isopropyluracil
• 英文别名: 5-prop-2-yl-2,4(1H,3H)-pyrimidinedione；5-propan-2-yl-1H-pyrimidine-2,4-dione
• CAS: 17432-95-0
• 化学式: C₇H₁₀N₂O₂
• 分子量: 154.169
• InChiKey: NWNKIJNFNJCAHN-UHFFFAOYSA-N

物化性质

• 熔点：
  288-289 °C
• 密度：
  1.142±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  5-异丙基尿嘧啶 在 sodium methylate 、 六甲基二硅氮烷 作用下， 以 甲醇 、 氯仿 为溶剂， 生成 依培夫定
  参考文献：
  名称：

  The Synthesis of Some 5-Substituted and 5,6-Disubstituted 2′-Deoxyuridines

  摘要：

  5-Alkyl(cycloalkyl)-2'-deoxyuridines VIa-VIf were synthesised in high yields by condensation of the corresponding silylated bases with 2-deoxy-3,5-di-O-p-toluoyl-D-erythro-pentosyl chloride in chloroform and subsequent deblocking with sodium methoxide in methanol. The beta-configuration, anti-glycosidic conformation and C2'-endo (S) sugar pucker of all of these compounds has been established from their H-1 NMR, C-13 NMR, UV and mass spectra. Under the same conditions, the condensation of silylated 5,6-trimethyleneuracil, resulted in 1:2/alpha:beta anomeric mixture (overall yield 71%) and syn-conformation of the 5,6-trimethylene-2'-deoxyuridine [Xg]. The results of the condensation of the silylated 5,6-dimethyluracil are discussed as well. No significant antiviral activity has been found in testing the synthesised compounds against a range of herpes, influenza and HIV-1 viruses.

  DOI：

  10.1080/15257779408013234
• 作为产物：
  描述：

  异戊酸甲酯 在 氯乙酸 、 lithium diisopropyl amide 作用下， 以 水 为溶剂， 反应 12.0h， 生成 5-异丙基尿嘧啶
  参考文献：
  名称：

  The Synthesis of Some 5-Substituted and 5,6-Disubstituted 2′-Deoxyuridines

  摘要：

  5-Alkyl(cycloalkyl)-2'-deoxyuridines VIa-VIf were synthesised in high yields by condensation of the corresponding silylated bases with 2-deoxy-3,5-di-O-p-toluoyl-D-erythro-pentosyl chloride in chloroform and subsequent deblocking with sodium methoxide in methanol. The beta-configuration, anti-glycosidic conformation and C2'-endo (S) sugar pucker of all of these compounds has been established from their H-1 NMR, C-13 NMR, UV and mass spectra. Under the same conditions, the condensation of silylated 5,6-trimethyleneuracil, resulted in 1:2/alpha:beta anomeric mixture (overall yield 71%) and syn-conformation of the 5,6-trimethylene-2'-deoxyuridine [Xg]. The results of the condensation of the silylated 5,6-dimethyluracil are discussed as well. No significant antiviral activity has been found in testing the synthesised compounds against a range of herpes, influenza and HIV-1 viruses.

  DOI：

  10.1080/15257779408013234

文献信息

• [EN] PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES<br/>[FR] COMPOSÉS PYRAZOLO[3,4-B]PYRIDINE UTILISÉS EN TANT QU'INHIBITEURS DE KINASES TAM ET MET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2020047184A1

  公开（公告）日：2020-03-05

  Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

  本文提供了Formula (I)的化合物及其立体异构体、互变异构体和药学上可接受的盐，其中R1、R2、R9、X1和G如本文所定义，它们是一种或多种TAM激酶和/或c-Met激酶的抑制剂，并且在治疗和预防可以用TAM激酶抑制剂和/或c-Met激酶抑制剂治疗的疾病中非常有用。
• [EN] 2-(3,5-DISUBSTITUTEDPHENYL)PYRIMIDIN-4(3H)-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-(3,5-DISUBSTITUTEDPHENYL)PYRIMIDIN-4(3H)-ONE
  申请人：PFIZER

  公开号：WO2011158149A1

  公开（公告）日：2011-12-22

  O N NH R3 R2 O R1 168 ABSTRACT The present invention provides a 2-(3,5-disubstitutedphenyl)pyrimidin- 4(3H)-one compound of Formula (I) 5 (I) or a pharmaceutically acceptable salt thereof wherein R 1, R2 and R3 are as defined herein. The compounds of Formula (I) have been found to act as glucokinase activators. Consequently, the compounds of Formula (I) and 10 the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucokinase.

  本发明提供了一种Formula (I)的2-(3,5-二取代苯基)嘧啶-4(3H)-酮化合物或其药学上可接受的盐，其中R1、R2和R3如本文所定义。已发现Formula (I)的化合物可作为葡萄糖激酶激活剂。因此，Formula (I)的化合物及其药物组成物对于治疗由葡萄糖激酶介导的疾病、紊乱或症状是有用的。
• [EN] NOVEL COMPOUNDS AND THEIR USES AS THYROID HORMONE RECEPTOR AGONISTS<br/>[FR] NOUVEAUX COMPOSÉS ET LEURS UTILISATIONS EN TANT QU'AGONISTES DU RÉCEPTEUR DE L'HORMONE THYROÏDIENNE
  申请人：NANJING RUIJIE PHARMA CO LTD

  公开号：WO2020169069A1

  公开（公告）日：2020-08-27

  A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto． (I), (Ia)

  提供了一种公式(I)或(Ia)的化合物，或其同分异构体或药用可接受的盐。还提供了公式(II)至(V)的化合物，或其同分异构体或药用可接受的盐。这些化合物以及含有这些化合物的药物组合物可用于治疗肥胖、高脂血症、高胆固醇血症、糖尿病以及与这些疾病相关的其他疾病和障碍，并且可能对其他疾病如非酒精性脂肪肝炎(NASH)、动脉粥样硬化、心血管疾病、甲状腺功能减退、甲状腺癌以及与这些疾病和障碍相关的其他疾病有益。
• Pyrimidinedione, pyrimidinetrione, triazinedione and
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05859014A1

  公开（公告）日：1999-01-12

  Compounds of Formula I: ##STR1## where R.sup.5 is a group selected from Formulae (a), (b), (c) and (d): ##STR2## and the pharmaceutically acceptable salts and N-oxides thereof, are .alpha..sub.1 -adrenergic receptor antagonists useful for the treatment of diseases involving directly or indirectly an obstruction of the lower urinary tract, such as benign prostatic hyperplasia.

  化合物的化学式I：##STR1##其中R.sup.5是从式(a)、(b)、(c)和(d)中选择的基团：##STR2##以及其药用可接受的盐和N-氧化物，是用于治疗涉及直接或间接阻塞下尿道的疾病，如良性前列腺增生的α1-肾上腺素受体拮抗剂。
• Regioselective 2-Amination of Polychloropyrimidines
  作者：Sean M. Smith、Stephen L. Buchwald

  DOI：10.1021/acs.orglett.6b00799

  日期：2016.5.6

  The regioselective amination of substituted di- and trichloropyrimidines affording the 2-substituted products is reported. While aryl- and heteroarylamines require the use of a dialkylbiarylphosphine-derived palladium catalyst for high efficiency, more nucleophilic dialkylamines produce 2-aminopyrimidines under noncatalyzed SNAr conditions. The key is the use of 5-trimethylsilyl-2,4-dichloropyrimidine

  报道了提供2-取代产物的取代的二氯和三氯嘧啶的区域选择性胺化。尽管芳基胺和杂芳基胺需要使用二烷基联芳基膦衍生的钯催化剂才能实现高效率，但更多的亲核性二烷基胺在未催化的S N Ar条件下会产生2-氨基嘧啶。关键是使用5-三甲基甲硅烷基-2,4-二氯嘧啶作为母体二氯嘧啶的替代物。对于更具挑战性的情况，制备了2-氯-4-硫代甲氧基甲氧基类似物，并专门提供了所需的2-氨基-4-硫代甲氧基嘧啶产物。